SUMO2/3 Antibody (SM23/496), PE/Cy7, Novus Biologicals™

SUMO2/3

Monoclonal

PE-Cyanine7

PBS with 0.05% Sodium Azide

SUMO2

Recombinant human SUMO2 protein

0.1 mL

Primary

This monoclonal antibody reacts with both SUMO-2 and SUMO-3. The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO-1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO-1 utilizes Ubc9 for conjugation to several target proteins, which include MDM2, p53, PML and RanGap1. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO-1

Store at 4°C in the dark. Do not freeze.

Flow Cytometry

SM23/496

Flow Cytometry, Flow (Intracellular)

HSMT3, small ubiquitin-like modifier 2, SMT3A, SMT3B, SMT3H2, SUMO2, SUMO3

Mouse

Protein A or G purified

Apoptosis

6613.0

Human

IgG1 κ